All News

In a longitudinal cohort study, researchers identified 17 seemingly novel variants of the PDE6A retinitis pigmentosa gene, suggesting it may be amenable to gene therapy.

Can a population health framework focused on a certain set of patients with chronic disease (ie, chronic kidney disease [CKD]) improve care in the primary care setting?

With the impact of coronavirus disease 2019 (COVID-19) evident in patients with renal disease, a discussion at Kidney Week focused on ways to engage them in clinical trials.

Recognizing chronic kidney disease (CKD) can lead to earlier implementation of interventions among patients, ultimately reducing the risk of end stage renal disease, said Shweta Bansal, MD, FASN, associate professor of medicine in the nephrology division at the University of Texas Health Center at San Antonio.

Adults with obstructive sleep apnea who are not adherent to continuous positive airway pressure (CPAP) therapy were found to be more likely to be hospitalized with influenza than those who used CPAP.

AstraZeneca and Johnson & Johnson will restart trials of their vaccine candidates against coronavirus disease 2019 (COVID-19); the United States hits a record high 2-day total of COVID-19 infections; strategies can help ease stress amid the coming election.

Although renal replacement therapy is a clinically meaningful end point, trials must include numerous patients and follow them for long periods of time, said Kunihiro Matsushita, MD, an associate professor in the Department of Epidemiology and Division of Cardiology at Johns Hopkins University.

Understanding patients’ social determinants of health (SDOH), including their past experiences with discrimination and medical mistrust, can help improve patient-reported outcomes (PROs), according to new research.

During Kidney Week, various studies discussed not only the effect coronavirus disease 2019 (COVID-19) has on patients with end-stage renal disease (ESRD) but also new attacks of acute kidney injury (AKI) that can cause severe illness or even death.

The use of estimated glomerular filtration rate (eGFR) equations in assessing chronic kidney disease (CKD) for Black patients may lead to underdiagnosis and undertreatment, according to a nephrologist speaking at Kidney Week.

Several symptoms patients with chronic kidney disease (CKD) experience are approved indications for medical cannabis, said Joshua L Rein, DO, FASN, a nephrologist at Mt. Sinai Hospital in New York City.

Initial preliminary efficacy and safety data are expected sometime next year, stated Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed the potential benefits of using CAR T-cell therapies as a second-line treatment.

In reviewing the previous literature on health disparities in kidney disease, there is not a lot described in patients with kidney pathologies outside of ESKD and dialysis, said Jill Krissberg, MD, a pediatric nephrology fellow at Stanford University School of Medicine.

After conducting further genome-wide association studies (GWAS), we will be able to inform communities about the potential implications of gene expression in their kidneys, said Adriana Hung, MD, MPH, associate professor of medicine at Vanderbilt University in an interview with Bryce Rowan, a statistical genetic analyst.

Additional studies about roxadustat, a drug in the new class of hypoxia-inducible factor stabilizers, were released during Kidney Week; one of them explored its role in lowering cholesterol in patients with chronic kidney disease (CKD) and anemia.

New results from EMPEROR-Reduced presented at Kidney Week 2020.

The decision to go on dialysis is often automatic, but using a shared decision-making process reduces the chance that a patient will regret it later.

In the first wave of the coronavirus disease 2019 pandemic, patients with axial spondyloarthritis, rheumatoid arthritis, and psoriatic arthritis didn’t have an increase in disease activity despite an interruption in in-person interactions.

Aligned with recommendations published through the Choosing Wisely Campaign, pediatric sleep studies should be performed and interpreted according to pediatric, not adult, standards.

People who experience acute kidney injuries (AKIs) in the hospital have higher rates of cardiac disease and death compared with those who have been discharged, said Benjamin Griffin, MD, a nephrologist and assistant professor of internal medicine at the University of Iowa.

Their study outlines several treatments being investigated for the treatment of patients with myelofibrosis and other myeloproliferative neoplasms, generally after they have become resistant or intolerant to Janus kinase inhibition.

Finerenone slowed chronic kidney disease (CKD) progression by 18% and cut cardiovascular (CV) events by 14%, according to phase 3 trial results.

High incidence of kidney failure in minority groups can be attributed to faster progression of kidney function decline in these populations, said Guofen Yan, PhD, associate professor of biostatistics in the department of public health sciences at the University of Virginia School of Medicine.

While sickle cell disease is not prevalent in the general population, the significant cost associated with the condition warrants action from payers and formulary decision makers to improve patient access and align cost with their budgetary goals.

Despite the benefits of switching to a different mode of action in the second line, almost half of patients with rheumatoid arthritis were cycled to a second tumor necrosis factor inhibitor.

In her presentation, Aimee Tharaldson, PhD, senior clinical pharmacist of emerging therapeutics at Express Scripts, discussed the upcoming pipeline of specialty drug approvals and their potential impact on the market.